查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451738

2024-2032 年按類型（1 型、2 型等）、診斷和治療（診斷、治療）、最終用戶（醫院、家庭護理、專科診所等）和地區分類的法布瑞氏症市場報告

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球法布瑞氏症市場規模達到20億美元。展望未來， IMARC Group預計到2032年市場規模將達到36億美元，2024-2032年複合年成長率（CAGR）為6.34%。患有法布瑞氏症的患者數量不斷增加，以及對遺傳和酵素替代療法等有效新療法的需求不斷增加，是推動市場發展的一些關鍵因素。

法布瑞氏症或α 半乳糖苷酶A 缺乏症是一種嚴重的X 連鎖溶小體遺傳性疾病，由缺乏代謝各種脂質儲存和脂肪樣成分（包括油、脂肪酸和蠟）所需的酶引起。如果不及時診斷或治療，可能會導致血管和組織阻塞、進行性腎衰竭、神經損傷，甚至中風。目前，法布瑞氏症可以在酵素替代療法（ERT）和輔助療法的支持下進行治療。除此之外，還可以透過基因、血液、腸外檢查進一步確診，抑制腎臟、心臟問題的發生。這些方法可防止發生一級和二級併發症的風險，並糾正潛在的酵素缺乏症。因此，醫院和專科診所廣泛利用各種程序來及時診斷和有效治療法布瑞氏症。

法布瑞氏症市場趨勢：

患有法布瑞氏症的患者數量不斷增加，以及對精確有效療法的需求不斷增加，例如遺傳、酵素替代底物減少和穩定個體免受疾病影響的伴侶治療，是推動市場成長的主要動力。與此一致的是，對用於疾病治療的口服藥物和膠囊的需求不斷成長是另一個成長誘導因素。此外，監管機構為投資醫療保健產業以設計突破性疾病治療方案所採取的有利措施正在支持市場成長。此外，重大技術進步，例如用於診斷和治療法布瑞氏症的遠距醫療解決方案和家庭護理設置的引入，有利於市場成長。人們對該疾病的認知不斷提高，也大大推動了市場的發展。醫生和個人對早期診斷和多種預防措施的可用性的認知不斷增強，這有助於市場的成長。老年人口不斷增加，容易患任何慢性病，這是推動市場成長的另一個因素。其他因素，例如醫療保健基礎設施的顯著改善、對遺傳疾病療法進步的更加關注以及擴大治療和藥物組合的持續研發（R＆D）活動，正在為市場創造積極的前景。

本報告回答的關鍵問題：

  • 迄今為止，全球法布瑞氏症市場表現如何，未來幾年將如何表現？
  • 全球法布瑞氏症市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的法布瑞氏症市場？
  • 依類型分類市場是怎麼樣的？
  • 基於診斷和治療的市場區隔是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 全球法布瑞氏症市場的競爭結構如何？
  • 全球法布瑞氏症市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球法布瑞氏症市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 類型1
    • 市場走向
    • 市場預測
  • 2型
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：透過診斷與治療

  • 診斷
    • 市場走向
    • 關鍵環節
      • 驗血
      • 基因檢測
      • 腸外試驗
      • 其他
    • 市場預測
  • 治療
    • 市場走向
    • 關鍵環節
      • 酵素替代療法
      • 口腔治療
      • 輔助治療
      • 其他
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 居家護理
    • 市場走向
    • 市場預測
  • 專科診所
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amicus Therapeutics
    • Freeline
    • Idorsia Pharmaceuticals Ltd
    • JCR Pharmaceuticals Co. Ltd
    • Protalix BioTherapeutics
    • Sangamo Therapeutics Inc.
Product Code: SR112024A6668

The global fabry disease market size reached US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.34% during 2024-2032. The increasing number of patients suffering from fabry disease and the escalating need for effective novel therapies, such as genetic and enzyme replacement therapy, represent some of the key factors driving the market.

Fabry disease, or alpha galactosidase-A deficiency, represents a severe x-linked lysosomal inherited disorder that is caused by the lack of enzymes that are required to metabolize various lipid storage and fat-like components, including oils, fatty acids, and waxes. If left undiagnosed or untreated, it might result in clogging of blood vessels and tissue, progressive kidney failures, nerve damage, and even strokes. Currently, fabry disease can be treated with the support of enzyme replacement therapies (ERT) and adjunct therapy. Apart from this, it can be further diagnosed through genetic, blood, and parenteral examinations to inhibit the occurrence of kidney and heart problems. These approaches prevent the risk of developing first and second-level complications and correct underlying enzyme deficiency. Consequently, hospitals and specialty clinics widely utilize various procedures for the timely diagnosis and effective treatment of the Fabry disease.

Fabry Disease Market Trends:

The increasing number of patients suffering from fabry disease and the escalating need for precise and effective therapies, such as genetic, enzyme replacement substrate reduction, and chaperone treatments to stabilize individuals from suffering disease, are primarily driving the market growth. In line with this, the rising demand for orally administered medications and capsule for disease treatment is acting as another growth-inducing factor. Additionally, the favorable initiatives being undertaken by regulatory bodies to invest in the healthcare sector for the designing of breakthrough disease treatment options are supporting the market growth. Moreover, significant technological advancements, such as the introduction of telemedicine solutions and home care settings for the diagnosis and treatment of Fabry disease, are favoring the market growth. The market is also significantly driven by the rising awareness regarding the disease. There is an increasing consciousness regarding the availability of early-stage diagnosis and multiple preventive measures amongst physicians and individuals, which is contributing to the market growth. The steadily increasing geriatric population, which is susceptible to any kind of chronic ailments, is another factor contributing to the market growth. Other factors, such as significant improvements in the healthcare infrastructure, an enhanced focus on the advancement of the genetic disease therapies, and continuous research and development (R&D) activities to expand treatment and medication portfolios, are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global fabry disease market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, diagnosis and treatment, and end user.

Type Insights:

Type 1

Type 2

Others

The report has also provided a detailed breakup and analysis of the fabry disease market based on the type. This includes Type 1, Type 2 and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Test

Genetic Test

Parenteral Test

Others

Treatment

Enzyme Replacement Therapy

Oral Therapy

Adjunct Therapy

Others

A detailed breakup and analysis of the fabry disease market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood test, genetic test, parental test, and others) and treatment (enzyme replacement therapy, oral therapy, adjunct therapy, and others).

End User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the fabry disease market based on the end user has also been provided in the report. This includes hospitals, homecare, specialty clinics and others. According to the report, specialty clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Fabry disease. Some of the factors driving the North America fabry disease market included the increasing prevalence of fabry disease and the ongoing approvals of advanced therapeutics by regional governments for the disorder treatment.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global fabry disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics, Freeline, Idorsia Pharmaceuticals Ltd, JCR Pharmaceuticals Co. Ltd, Protalix BioTherapeutics, Sangamo Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global fabry disease market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global fabry disease market?
  • What are the key regional markets?
  • Which countries represent the most attractive fabry disease markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the diagnosis and treatment?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global fabry disease market?
  • Who are the key players/companies in the global fabry disease market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Fabry Disease Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Type 1
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Type 2
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Test
      • 7.1.2.2 Genetic Test
      • 7.1.2.3 Parenteral Test
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Enzyme Replacement Therapy
      • 7.2.2.2 Oral Therapy
      • 7.2.2.3 Adjunct Therapy
      • 7.2.2.4 Others
    • 7.2.3 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Specialty Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amicus Therapeutics
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Freeline
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Idorsia Pharmaceuticals Ltd
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 JCR Pharmaceuticals Co. Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Protalix BioTherapeutics
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Sangamo Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Fabry Disease Market: Major Drivers and Challenges
  • Figure 2: Global: Fabry Disease Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Fabry Disease Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Fabry Disease Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Fabry Disease Market: Breakup by Diagnosis & Treatment (in %), 2023
  • Figure 6: Global: Fabry Disease Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Fabry Disease Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Fabry Disease (Type 1) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Fabry Disease (Type 1) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Fabry Disease (Type 2) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Fabry Disease (Type 2) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Fabry Disease (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Fabry Disease (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Fabry Disease (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Fabry Disease (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Fabry Disease (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Fabry Disease (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Fabry Disease (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Fabry Disease (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Fabry Disease (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Fabry Disease (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Fabry Disease (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Fabry Disease (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Fabry Disease (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Fabry Disease (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Fabry Disease Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Fabry Disease Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Fabry Disease Industry: Value Chain Analysis
  • Figure 77: Global: Fabry Disease Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Fabry Disease Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Fabry Disease Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Fabry Disease Market Forecast: Breakup by Diagnosis & Treatment (in Million US$), 2024-2032
  • Table 4: Global: Fabry Disease Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Fabry Disease Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Fabry Disease Market: Competitive Structure
  • Table 7: Global: Fabry Disease Market: Key Players